Investors & Media
Company Overview
Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health. The Company has built a human-centric proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs.
Click here to view our Corporate Presentation.
Copyright West LLC.
Minimum 15 minutes Delayed.
Minimum 15 minutes Delayed.
Press Releases
Dec 12, 2019
Nov 06, 2019
Oct 30, 2019
Upcoming Events